@article{6ce1a1476e9843c3be2fb8b27b3c119a,
title = "The minimum clinically important difference: which direction to take",
abstract = "Over the past decades in modern medicine, there has been a shift from statistical significance to clinical relevance when it comes to interpreting results from clinical trials. A concept that is increasingly being used as a surrogate for clinical relevance and effect size calculation is the minimum clinically important difference (MCID). In this paper, an overview is presented of the most important aspects of the MCID concept used in research trials and a discussion of what this means for the neurological patient in clinical trials and daily practice is given. Is the MCID the best outcome measure cut-off to be implemented?",
keywords = "minimum clinically important difference (MCID), QUALITY-OF-LIFE, STATISTICAL SIGNIFICANCE, INTRAVENOUS IMMUNOGLOBULIN, INTRAINDIVIDUAL CHANGES, PATIENT, RELEVANCE, TRIAL",
author = "Draak, \{T. H. P.\} and \{de Greef\}, \{B. T. A.\} and Faber, \{C. G.\} and Merkies, \{I. S. J.\} and \{PeriNomS Study Grp\}",
note = "Funding Information: Ingemar S.J. Merkies received funding for research from the Talecris Talents programme, CIDP/GBS Foundation International, Prinses Beatrix Spierfonds and the European Union 7th Framework Programme (grant number 602273). Furthermore, a research foundation at the University of Maastricht received honoraria on his behalf for participation in steering committees of the Talecris ICE Study, Laboratoire fran{\textcopyright}cais du Fractionnement et des Biotechnologies, CSL Behring, Novartis, Grifols and Octapharma. He serves on the editorial board of the Journal of the Peripheral Nervous System, is a member of the Inflammatory Neuropathy Consortium and is a member of the Peripheral Nerve Society. Funding Information: Thomas H.P. Draak reports no disclosures. Bianca T.A. de Greef reports a grant from Prinses Beatrix Spierfonds (W.OR12-01), outside the submitted work. Catharina G. Faber reports grants from European Union{\textquoteright}s Horizon 2020 research and innovation programme Marie Sklodowska-Curie grant for PAIN-Net, Molecule-to-man pain network (grant no. 721841), grants from Prinses Beatrix Spierfonds (W.OR15-25), grants from Grifols and Lamepro for a trial on IVIg in small fibre neuropathy, and other from steering committees/advisory board for studies in small fibre neuropathy of Biogen/Convergence, Vertex and Chromocell, outside the submitted work. Publisher Copyright: {\textcopyright} 2019 The Authors. European Journal of Neurology published by John Wiley \& Sons Ltd on behalf of European Academy of Neurology.",
year = "2019",
month = jun,
doi = "10.1111/ene.13941",
language = "English",
volume = "26",
pages = "850--855",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "6",
}